<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04038827</url>
  </required_header>
  <id_info>
    <org_study_id>0037975</org_study_id>
    <nct_id>NCT04038827</nct_id>
  </id_info>
  <brief_title>Origin of CEC in Patients After Allo-HSCT</brief_title>
  <acronym>DCEC-PIANO</acronym>
  <official_title>Search of Circulating Endothelial Cells of Donor Origin After Allogeneic Hematopoietic Stem Cell Transplantation: Evaluation for Potential Clinically Relevant Implications in the Context of Graft-Versus-Host Disease</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Università degli Studi di Brescia</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Turin, Italy</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      We believe that CEC, besides coming from cells shedding from patient vasculature, could
      partly belong to donor, originating from the cellular graft.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In consideration of the fact that the vascular endothelium has been shown to be a target of
      GvHD in early stage and that the count of CEC represent a marker of endothelial damage, we
      want to correlate the presence of donor CEC at engraftment with a putative protective
      function against GVHD manifestations. We will enroll patients affected by hematologic
      disorders undergoing allo-HSCT. At time of engraftment and at + 3 months after allo-HSCT, CEC
      identified and counted by means of the CellSearch system, will be recovered from the counting
      cartridge and further sorted at the single cell level. STR profile of each single CEC
      recovered will be performed in order to define host versus donor origin of each CEC analysed.

      Through the conduct of this study, we expect to upfront identify patients who will or will
      not manifest GvHD. This result will allow definitely different clinical approaches: stringent
      monitoring and early therapeutic intervention, before refractory disease's development, in
      the formers, while, sparing unnecessarily expensive testing or heavier treatment in the
      latters.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 27, 2019</start_date>
  <completion_date type="Actual">April 30, 2020</completion_date>
  <primary_completion_date type="Actual">January 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Presence of D-CEC at time of engraftment in patients undergoing allo-HSCT</measure>
    <time_frame>Within 30 days from allo-HSCT</time_frame>
    <description>Single CEC will be isolated and STR profile determined</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlate presence/absence of D-CEC with GVHD manifestations</measure>
    <time_frame>day +100 post allo-HSCT</time_frame>
    <description>D-CEC presence will be correlated with GVHD onset</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Presence of donor CEC embedded in the endothelial layer of patients microvasculature at late timepoint after allo-HSCT</measure>
    <time_frame>day +100 post allo-HSCT</time_frame>
    <description>CISH analysis will be performed on tissue biopsies at 3 months post-transplant</description>
  </secondary_outcome>
  <enrollment type="Actual">15</enrollment>
  <condition>Graft Versus Host Disease, Acute</condition>
  <condition>Endothelial Dysfunction</condition>
  <condition>Immune Tolerance</condition>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>D-CEC counting</intervention_name>
    <description>By means of preliminary bulk separation step with the CellSearch system, single CEC will be sorted</description>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA will be obtained from each single CEC
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients undergoing allo-HSCT for their neoplastic hematologic disorders
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing allo-HSCT for their neoplastic hematologic diseases

          -  written informed consent

          -  achievement of hematopoietic recovery from aplasia post-allo-HSCT

          -  predictable life expectancy &gt; 6 months

        Exclusion Criteria:

          -  presence of active malignant hematologic disease at time of allo-HSCT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Camillo Almici, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>ASST Spedali Civili di Brescia</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>ASST Spedali Civili di Brescia</name>
      <address>
        <city>Brescia</city>
        <zip>25123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Penack O, Socié G, van den Brink MR. The importance of neovascularization and its inhibition for allogeneic hematopoietic stem cell transplantation. Blood. 2011 Apr 21;117(16):4181-9. doi: 10.1182/blood-2010-10-312934. Epub 2011 Jan 21.</citation>
    <PMID>21258010</PMID>
  </reference>
  <reference>
    <citation>Riesner K, Shi Y, Jacobi A, Kräter M, Kalupa M, McGearey A, Mertlitz S, Cordes S, Schrezenmeier JF, Mengwasser J, Westphal S, Perez-Hernandez D, Schmitt C, Dittmar G, Guck J, Penack O. Initiation of acute graft-versus-host disease by angiogenesis. Blood. 2017 Apr 6;129(14):2021-2032. doi: 10.1182/blood-2016-08-736314. Epub 2017 Jan 17.</citation>
    <PMID>28096092</PMID>
  </reference>
  <reference>
    <citation>Fadini GP, Avogaro A. Cell-based methods for ex vivo evaluation of human endothelial biology. Cardiovasc Res. 2010 Jul 1;87(1):12-21. doi: 10.1093/cvr/cvq119. Epub 2010 Apr 28. Review.</citation>
    <PMID>20427336</PMID>
  </reference>
  <reference>
    <citation>Lanuti P, Rotta G, Almici C, Avvisati G, Budillon A, Doretto P, Malara N, Marini M, Neva A, Simeone P, Di Gennaro E, Leone A, Falda A, Tozzoli R, Gregorj C, Di Cerbo M, Trunzo V, Mollace V, Marchisio M, Miscia S. Endothelial progenitor cells, defined by the simultaneous surface expression of VEGFR2 and CD133, are not detectable in healthy peripheral and cord blood. Cytometry A. 2016 Mar;89(3):259-70. doi: 10.1002/cyto.a.22730. Epub 2015 Aug 25.</citation>
    <PMID>26305912</PMID>
  </reference>
  <reference>
    <citation>Lanuti P, Simeone P, Rotta G, Almici C, Avvisati G, Azzaro R, Bologna G, Budillon A, Di Cerbo M, Di Gennaro E, Di Martino ML, Diodato A, Doretto P, Ercolino E, Falda A, Gregorj C, Leone A, Losa F, Malara N, Marini M, Mastroroberto P, Mollace V, Morelli M, Muggianu E, Musolino G, Neva A, Pierdomenico L, Pinna S, Piovani G, Roca MS, Russo D, Scotti L, Tirindelli MC, Trunzo V, Venturella R, Vitagliano C, Zullo F, Marchisio M, Miscia S. A standardized flow cytometry network study for the assessment of circulating endothelial cell physiological ranges. Sci Rep. 2018 Apr 11;8(1):5823. doi: 10.1038/s41598-018-24234-0.</citation>
    <PMID>29643468</PMID>
  </reference>
  <reference>
    <citation>Almici C, Skert C, Verardi R, Di Palma A, Bianchetti A, Neva A, Braga S, Malagola M, Turra A, Marini M, Russo D. Changes in circulating endothelial cells count could become a valuable tool in the diagnostic definition of acute graft-versus-host disease. Transplantation. 2014 Oct 15;98(7):706-12. doi: 10.1097/TP.0000000000000385.</citation>
    <PMID>25119132</PMID>
  </reference>
  <reference>
    <citation>Almici C, Skert C, Bruno B, Bianchetti A, Verardi R, Di Palma A, Neva A, Braga S, Piccinelli G, Piovani G, Malagola M, Bernardi S, Giaccone L, Brunello L, Festuccia M, Baeten K, Russo D, Marini M. Circulating endothelial cell count: a reliable marker of endothelial damage in patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant. 2017 Dec;52(12):1637-1642. doi: 10.1038/bmt.2017.194. Epub 2017 Sep 11.</citation>
    <PMID>28892085</PMID>
  </reference>
  <reference>
    <citation>Almici C, Neva A, Skert C, Bruno B, Verardi R, Di Palma A, Bianchetti A, Braga S, Piovani G, Cancelli V, Omedè P, Baeten K, Rotta G, Russo D, Marini M. Counting circulating endothelial cells in allo-HSCT: an ad hoc designed polychromatic flowcytometry-based panel versus the CellSearch System. Sci Rep. 2019 Jan 14;9(1):87. doi: 10.1038/s41598-018-36442-9.</citation>
    <PMID>30643152</PMID>
  </reference>
  <reference>
    <citation>Cortesini R, Suciu-Foca N. ILT3+ ILT4+ tolerogenic endothelial cells in transplantation. Transplantation. 2006 Jul 15;82(1 Suppl):S30-2.</citation>
    <PMID>16829792</PMID>
  </reference>
  <reference>
    <citation>Taflin C, Charron D, Glotz D, Mooney N. Regulation of the CD4+ T cell allo-immune response by endothelial cells. Hum Immunol. 2012 Dec;73(12):1269-74. doi: 10.1016/j.humimm.2012.07.009. Epub 2012 Jul 16. Review.</citation>
    <PMID>22813652</PMID>
  </reference>
  <reference>
    <citation>Pober JS. Is host endothelium a silver lining for allografts? Lancet. 2001 Jan 6;357(9249):2-3.</citation>
    <PMID>11197355</PMID>
  </reference>
  <reference>
    <citation>Wu SR, Reddy P. Tissue tolerance: a distinct concept to control acute GVHD severity. Blood. 2017 Mar 30;129(13):1747-1752. doi: 10.1182/blood-2016-09-740431. Epub 2017 Feb 2. Review.</citation>
    <PMID>28153825</PMID>
  </reference>
  <reference>
    <citation>Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000 Jan;105(1):71-7.</citation>
    <PMID>10619863</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 25, 2019</study_first_submitted>
  <study_first_submitted_qc>July 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 31, 2019</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia</investigator_affiliation>
    <investigator_full_name>Camillo Almici MD</investigator_full_name>
    <investigator_title>Director of the Stem Cells Lab</investigator_title>
  </responsible_party>
  <keyword>Circulating Endothelial Cells</keyword>
  <keyword>Graft versus Host Disease</keyword>
  <keyword>Neovascularization</keyword>
  <keyword>Allotransplantation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
    <mesh_term>Acute Disease</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>The datasets generated and analyzed during the current study will be available from the corresponding author on reasonable request after publication of results</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>after publication of results</ipd_time_frame>
    <ipd_access_criteria>Request to Principal Investigator</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

